All posts from Andreas
Andreas in Gainers & Losers,

Regeneron releases upbeat report for Q3

Biopharmaceutical company Regeneron Pharmaceuticals (REGN) released a robust financial report for 3Q15. Revenue rose 57% y-o-y to USD 1.14 bn, outpacing analysts’ expectations by USD 80 mn. The company’s main drug EYLEA (intended to treat macular edema associated with age-related macular degeneration) became a revenue growth driver with the top line surging 65% y-o-y to USD 734 mn, making 64% of total revenue. Adjusted EPS jumped 37% y-o-y to USD 3.47, outpacing the consensus by 27 cents. The company revised up forecast of EYLEA sales from 45-50% to 50-55%.

Regeneron develops a number of new drugs. Praluent, intended to lower cholesterol, was launched into production in July 2015. The company also works on four drugs, which are on the third stage of clinical trials and will be launched in production in the near future.

I believe that successful promotion of EYLEA and Praluent, as well as the launch of new drugs will help to improve the company’s financial performance and assign a Buy recommendation to the name in the mid-term.